It is believed that most malignancies become more common with increasing age due to the requirement for several mutations to accumulate and subsequently interact. The age specific incidence of acute promyelocytic leukemia (APL) was investigated using population-based data from 77 million subject years of observation, yielding 149 consecutive cases. The incidence appears approximately constant with respect to age, an observation not previously reported with any other malignancy. These findings are most easily explained by there being only one rate limiting genetic event required to initiate the disease, although other, non-rate limiting mutations may also be necessary for disease development. It is also argued that this mutation is probably restricted to cells committed to differentiation, which may explain why APL is curable by chemotherapy. Leukemia (2000) 14, 722-726.
Introduction
The pathogenesis of malignant transformation is generally believed to be a multistep process involving a series of somatic mutations which must interact to produce a malignant phenotype; 1 it is this requirement for several mutations to interact that is thought to underlie the increase in malignancy rate with age. How many rate limiting mutations are generally required is currently uncertain, this question being difficult to address experimentally. 2 Analysis of epidemiologic data can provide insights into the problem; notably, the two hit model for retinoblastoma. 3 The incidence of most malignancies rises as the fourth to fifth power of age. This observation has been interpreted as indicating five or six rate limiting mutations, 1, 4 although the underlying reasoning is open to doubt, due to the mutation rate being too low and uncertainty about clonal evolution. 5, 6 Acute promyelocytic leukemia (APL), a sub-type of acute myeloid leukemia, is an unusual malignancy. It is characterized by the accumulation of immature promyelocytes, 7 which cause fibrinolysis and hemostatic failure. 8 Cytogenetically, it is usually associated with a pathognomonic translocation, t (15;17) , juxtaposing the gene for the retinoic acid ␣ receptor (RAR␣) with the PML gene. 9 It is the only malignancy for which differentiation therapy is a well established part of therapy. 10 The epidemiology of acute promyelocytic leukemia (APL) is also unusual in that the average age of presentation is relatively low but both young and old are commonly affected. This paper reports a formal analysis of the age dependence of APL.
In considering the implications of the age dependence that we describe, it is assumed that the mutation rate is constant.
Evidence for this view comes from many sources. The age of the organism from which cells are obtained has not been found to be an important determinant of their mutation rate. Susceptibility to mutagen-induced carcinogenesis is usually independent of age, both in experimental animals and humans. 11 Finally, the accumulation of bone marrow mutations in humans can be accounted for by the underlying kinetics of cell division, with a linear increase with age and little evidence for any variation in the underlying mutation rate. 12 We therefore consider the assumption of a constant mutation rate to be reasonable, although not proven.
Subjects and methods
One hundred and fifty-nine cases of APL were ascertained from four British Regional Leukemia Registries. Importantly for a study of this type, such Registries collect cases from a defined population without bias with respect to age, unlike trials. The data on each Register are maintained by interested hematologists. Cases were ascertained from: Merseyside (January 1987-May 1994); Northern (January 1988-July 1998); North-West (January 1992-May 1994); Oxford (January 1989-May 1995). In addition to prospective reporting, every hematologist in the regions was contacted and asked about any other cases. Each case was confirmed by discussion with the clinicians and regional cytogenetics laboratories.
Accuracy of case ascertainment
The diagnosis of APL was initially made on morphological grounds by the local hematologists; diagnostic slides were reviewed centrally in each region and only after confirmation of FAB M3 were they accepted into the study. Cytogenetic analysis was attempted in all but 21 cases. In a further nine cases the analyses failed and in seven patients a normal karyotype was found. Fluorescent in situ hybridization (FISH) analysis was used in three of these seven and the PML-RAR␣ translocation detected in two cases. Detection of the translocation by PCR was not routinely performed. On only one patient was the t(11;17) translocation detected. In all other patients the typical t(15;17) translocation was found. In three regions (118 cases), it was possible to obtain accurate information on additional abnormalities. In 14/118 cases (12%), t(15;17) was seen in the context of more complex abnormalities. The commonest was trisomy 8 (+8) as the sole additional abnormality (10/118; 9% cases).
The sizes and age structure of the relatively well characterized and stable populations were obtained from the Office of Population Censuses and Surveys; local and health authority areas (1991). The number of individuals with any given age was assumed to be constant within each of the given age categories. For the final age category, 50% of the over 75 category was assigned to the 75-80 years of age and 50% to 80-90 years of age.
Analysis and results
We start by discussing a simplistic analysis of the expected age-specific incidence if one, two or more independent rate limiting mutations were required for the development of APL.
Suppose that APL were caused by a single mutation. If the mutation rate is constant throughout life, it can be intuitively seen that the incidence at any age, I, would not be expected to vary with respect or age, or
where k 1 is a rate constant. Suppose that a malignancy were the result of two independent mutations and once a mutation occurred, it could persist for the rest of a lifetime. The cumulative probability of two mutations occurring in the same cell is then the product of the cumulative probabilities of the two individual mutations and the risk at any age is the first derivative. So,
where k 2 is a rate constant. In the general case, if the number of required mutations is n then
A further complication arises from the assumption that a cancer presents as soon as the final mutation takes place, which is implausible. If the mean latent period is defined as w, then equation (3) becomes
Indeed, it has been observed that the incidences of most cancers follow a fixed power of age, with an exponent of four to five. This observation has been widely interpreted to mean that five or six rate limiting mutations are necessary. In fact, this interpretation is almost certainly incorrect as the observed mutation rate is many orders of magnitude too low to allow such a number of independent mutations to accumulate by chance. Instead, it seems likely that an intermediate number of mutations effect a phenotypic change which causes the accumulation of subsequent interacting mutations to be more likely and therefore not independent. Detailed discussion of this problem is beyond the scope of this paper. 5 For present purposes, it should be noted that if more than one rate limiting mutation causing APL is postulated, the incidence should rise with age. If as few as two rate limiting mutations are necessary, the incidence should rise linearly with age, ie the exponent n in equation (4) would be one. If the first mutation were to make the second mutation progressively more likely, then the exponent n in equation (4) would be greater than 1. Conversely, if two mutations were required and the observed exponent was less than one then additional mechanisms must be postulated to account for the discrepancy. Such mechanisms might include the first mutation effecting a phenotypic change so that the probability of the second mutation becomes progressively lower, or the size of the APL precursor cell population decreasing progressively with age. At present, neither the nature nor the number of APL precursor cells are known, let alone how that number changes with age. While
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Figure 1
The reciprocal of the residual from least squares analysis ( there is some evidence that some compartments decrease in number with age, other compartments may increase. 13 In order to measure the age specific incidence of APL, we collected all diagnosed cases from 77 million subject years of observation, yielding 149 cases. The data were analysed using an extension of equation (4),
where I c is the cumulative number of cases at any age, P age the size of the population at each age, k a rate constant, t the age when the final rate limiting somatic mutation took place and w the latent period.
The optimum values of the rate constant, k, and latent period, w, were calculated for a variety of values of postulated exponent, n, between −1 and 1 by minimising the difference between observed and predicted values by least squares analysis. The minimum difference obtained was plotted against postulated n (Figure 1) , which yields the most likely parameter values as n = 0.09, w = 11.0 years and k = 3.14 per million individuals per year ( Figure 2 ). It is concluded that the age-specific incidence of APL is approximately constant over most of the age range.
Figure 2
The cumulative number of cases is plotted against age. Both the observed number (light dotted line) and the predicted number (dark line) of cases, using the optimised values as defined in the text, are shown.
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An alternative approach uses a Poisson heterogeneity test, which tests the hypothesis that the number observed during each time period does not deviate from the number expected for the population at that age. The statistic
on the null hypothesis of a constant rate, approximately follows a X 2 distribution. Considering intervals of 5 years, the P value for ages above 10 is 0.2 and so does not differ significantly from that expected by chance alone. Incorporation of childhood values decreases the P value to just less than 0.05. It is concluded that the distribution of values does not differ significantly from that predicted by a constant rate during adult life. In contrast, if the expected incidence is chosen on the basis of two rate limiting steps as predicted by equation (2) , the P value is Ͻ0.001, implying that the observed values are highly unlikely to be predicted by equation (2) . It is concluded that a multiple rate limiting hit model of APL cannot easily account for the observations presented here without postulating other mechanisms that would alter the age-specific incidence as discussed above.
Discussion
We have presented two statistical analyses, both of which support the hypothesis that the incidence of APL is approximately constant over most of the age range. While more sophisticated analyses might be applied, we feel that the major uncertainties in this analysis are not statistical but related to the raw data as discussed above and the interpretation, as discussed below.
The relatively low rate over the age of 70 may be explained by worse case ascertainment. It appears that the hemorrhagic tendency caused by APL is particularly prone to cause early death in elderly individuals 14 and so it is plausible that APL might present with, for example, fatal stroke before other clinical manifestations allow accurate diagnosis. Other explanations for the low rate in old age include the number of APL progenitor cells falling along with general bone marrow cellularity.
In this survey, a relatively low rate is seen during childhood. This was 'explained' in the mathematical analysis by the latent period. However, other explanations are possible. For instance, it is plausible that the number of APL progenitor cells is lower during childhood. If this were the case, then the mean latent period would be correspondingly lower.
If it is accepted that the incidence of APL is constant during adult life, can any conclusions be drawn concerning the biological basis of the disease? The most obvious implication is that it is difficult to reconcile a conventional multi-hit model of carcinogenesis with the data. If rate limiting mutations are viewed as gradually accumulating throughout life and several are required to interact to cause cancer, then the incidence should increase with age unless some other mechanism, apparently peculiar to APL, and possibly other myeloid translocations, is postulated that makes the accumulation or interaction of mutations progressively less common.
The simplest explanation of the data is that APL is caused by a single rate limiting mutation, where the distinction between 'rate limiting' and 'necessary' mutations is important. To illustrate the difference, consider a mutation 'A', that prevented apoptosis or differentiation but allowed cell division at a normal rate; each cell division would then result in two progeny and the resulting clone would grow exponentially. Suppose that a single further mutation, 'B', was also required to cause clinical presentation as a malignancy. By the time the clone resulting from the first mutation had undergone only 24 division cycles, the number of cells would reach 10 7 cells and, if the mutation rate for mutation B were a typical 10
per division, each cycle of divisions would result in a mean of 1 new B mutation in that clone. Mutation A would then be the only rate limiting mutation. Mutation B is still necessary for clinical presentation but its main kinetic contribution would be towards the latent period. The approach outlined here analyzes primarily the number of rate limiting mutations. There might be either zero or several other necessary but nonrate limiting mutations, which the approach presented here cannot distinguish between. This approach also cannot shed light on which mutations are involved. It is clearly simplest to equate the putative single event with the translocations involving the retinoic acid receptor but this is not necessarily the case. For instance, the rate limiting mutation might make the observed translocations so likely that their occurrence is no longer rate limiting.
One further, more complex explanation of our data should also be considered. More than one rate limiting mutation might be required but those mutations might both occur in cells committed by differentiation. In this scenario, both mutations would be occurring on many occasions in differentiating cells, with the time available for interaction with other mutations limited by the lifespan of the differentiating cells. The occurrence of both mutations in a single cell would then be expected to follow zero order kinetics, as observed. Although possible, we consider this to be an unlikely explanation as the spontaneous translocation rate is probably too low. Measurements of random translocation frequency in lymphocytes, 15 combined with estimates of lymphocyte turnover, 16 yield an approximate estimate of translocation rate of 10 −12 per base pair per division. A translocation involving both APL and RAR␣ loci would then occur at a rate of about 10 −18 per division. This figure gives an annual incidence reasonably close to that observed if it is estimated that 1% of marrow mitoses occur before the promyelocytic stage and are at risk of causing APL. The requirement of a second mutation would decrease the expected annual incidence by about 10 −7 , too far below that observed. Of course, this calculation involves many assumptions and approximations so that the requirement for two or even more mutations cannot be rigorously excluded. In this context, it would be valuable to have an estimate of the PML-RAR␣ mutation rate based on direct experimental evidence. In conclusion, more than one rate limiting mutation is possible if all mutations were confined to cells committed to differentiation but observed translocation rates are probably too low to sustain more than one rate limiting mutation.
The best fit latent period was 11 years, which might be considered a long time if other mutations were not required. Experimental evidence concerning whether other mutations are required is presently inconclusive. The most pertinent evidence in this regard arises from transgenic experiments where the introduction of PML-RAR␣ fusion genes generally result in acute leukemias but with variable latent periods of many months. However, these experiments are difficult to interpret due to uncertainty about the level of expression and cell types affected by transgenic expression. 17 When PML-RAR␣ was expressed in non-hematopoietic cells, not only were viable animals difficult to obtain but tumors in non-hematopoietic organs were observed, sometimes with latent periods as short as a few days. 18 While expression limited to late myeloid development (CD11b promoter), myeloid maturation was impaired but no leukemia resulted. 19 Using a Cathepsin G promoter, which is expressed during a window of promyelocyte maturation, a preleukemic syndrome was noted with 10-30% animals developing leukemia with a mean latent period of 300 days. 20, 21 As in human APL, all mice relapsed on ATRA treatment, which might seem to imply that other oncogenic lesions are present. On the other hand, ATRA resistance can result from mutations in the fusion protein itself 22 or it is possible that the reciprocal fusion protein also possesses oncogenic activity. The mouse model that is most similar to the human APL utilizes the MRP8 promoter, normally expressed at the promyelocyte to metamyelocyte stage and into mature neutrophils. A preleukemic phase is observed, with a syndrome similar to human APL developing in about one third after a median latency of 6 months. 23 The simplest explanation for the latency periods observed in all these models is that other genetic events are necessary. Unfortunately, no clonality studies have yet been reported on the transgenic mice.
The recent substantial progress in understanding the molecular basis of APL might also inform the debate on how many mutations are required. In virtually all cases, APL is associated with translocations resulting in a fusion protein, juxtaposing the C terminal portion of the RAR␣ receptor with the N terminal portion of one of four other partners, most commonly PML, resulting in a protein that is hyporesponsive to retinoic acid. 24 The retinoic acid response is clearly necessary for normal myeloid differentiation. In its non-ligand activated form, RAR␣ binds a number of corepressors, notably N-CoR and SMRT, which are part of a multiprotein repressor complex containing Sin3A corepressor and histone deacetylases. 25 It is believed that RAR␣ can inhibit transcription from certain promoters by alterations in chromatin structure resulting in a failure of the transcriptional machinery to access those promoters. Binding of retinoids results in heterodimerization of RAR␣ and RXR and binding with a number of coactivator proteins, which together stimulate transcription from a number of genes with retinoid response elements through interaction with basal factors, alteration of chromatin notably histone acetylation and DNA unwinding. 24 As both an excess of wildtype 26 and mutant 27 forms of RAR␣ are able to cause a differentiation block, a dominantly acting squelching mechanism whereby coactivators are sequestered is believed to operate. In addition, PML-RAR␣ homodimers can compete with normal RAR␣-RXR and also bind a novel set of target elements. 28, 29 To this already complex picture must be added further functions of the partner proteins of RAR␣ in the translocation. PML has the ability to both stimulate and inhibit transcription from various genes. PML is also a growth suppressor with tumor suppressor functions, perhaps involved in the reaction to viral infection. 24 In addition, PML containing nuclear bodies has also been associated with nascent mRNA, 30 and PML has been found associated with the transcriptional coactivator CBP and the AP1 DNA binding complex. 31 Finally, APL has been described in association with the RAR␣/PML rather than PML/RAR␣. 32, 33 The second commonest of the RAR␣ fusion partners, PLZF, colocalizes with and may be a key interaction partner of PML. All cases have been associated with the presence of the reciprocal translocation partner, which may have an important proliferative induction role. 24 Less is known about the roles of the other two fusion partners, nucleophosmin NPM, and nuclear matrix-mitotic apparatus protein, NuMA, Leukemia although it is clear that both are associated with the nuclear matrix and are associated with several nuclear processes. 24 Thus a complex picture of RAR␣ function is emerging whereby several domains within the receptor have different functions, some inhibitory and some stimulatory to transcription at a wide variety of genes important in myeloid development. Disruption of function by the formation of a single fusion protein results in many dominantly acting pleiotropic effects; so, even though several different phenotypes may be required for full malignant transformation, it is plausible that such a complex protein, together with effects from the reciprocal fusion protein, could supply several or even all the required phenotypes.
Our analysis also provides further, indirect evidence that the rate limiting event occurs in cells which are committed to differentiation. We have argued that the distribution of mutations in stem cells is complex, being skewed and those from early life being overrepresented; 12,38 so it seems unlikely that the simple relationship we have demonstrated here arises from stem cells. In contrast, mutations from more differentiated cells appear to be approximately constant throughout life, 12, 38 implying the event causing APL is restricted to cells committed to differentiation, a conclusion for which there is other experimental evidence. [34] [35] [36] [37] Presumably, the mutation rate for the PML/RAR␣ translocation is so low that its occurrence is negligible in cells as infrequent and slowly dividing as stem cells. Only the much greater number of cell divisions that occur during differentiation allow a sufficient probability of mutation to cause disease at the observed rates. Similar reasoning might explain why oncogenic translocations are generally restricted to childhood and hematopoietic malignancies, situations where mitoses are frequent. The observation that translocations are associated with relatively high care rates by chemotherapy, as exemplified by APL, may be explained by their acting as markers of the cell of origin being committed to differentiation rather than any other intrinsic properties.
In conclusion, analysis of the age-specific incidence of APL suggests it is approximately constant over most of the age range. It is argued that this observation implies the disease is due to a single rate limiting mutation and any necessary mutations are confined to cells which are committed to differentiation. While such arguments can never be regarded as proof, it is hoped that the reported observation adds to the debate on the number of mutations required to cause APL. Certainly, the molecular scenario deduced from various experimental techniques must be consistent with the epidemiological observations. In particular, it should be realized that the observation of a constant age-specific incidence, if confirmed in other series, is difficult to reconcile with more than one rate limiting mutation. We look forward to reports of similar analyses on other series of APL and other myeloid translocations.
